ArticleMolecular medicine reports2021
MicroRNA‑199a‑3p inhibits ovarian cancer cell viability by targeting the oncogene YAP1.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Understanding How Pregnancy Protects Against Ovarian and Endometrial Cancer Development: Fetal Antigens May Be Involved.Endocrinology · 2022Review
- miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer.International journal of molecular sciences · 2022Review
- The Role of microRNA in Pancreatic Cancer.Biomedicines · 2021Review
Corrections and comments
- Retraction · 2022-11-11Original Data and/or Images not Provided and/or not Available ·
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA‑199a‑3p (miR‑199a‑3p) is aberrantly expressed in various types of cancer where it exhibits a tumor suppressive role. However, the biological role of miR‑199a‑3p in ovarian cancer (OC) remains unclear. The present study aimed to investigate whether miR‑199a‑3p was a tumor suppressor in OC and to identify the possible mechanisms. It was found that miR‑199a‑3p expression was significantly downregulated in the tumor tissues and blood samples of patients with OC, as well as in three OC cell lines. In addition, its low expression was closely associated with International Federation of Gynecology and Obstetrics disease stage, histological grade and lymph node metastasis. It was demonstrated that overexpression of miR‑199a‑3p inhibited the viability and promoted apoptosis of OV90 and SKOV‑3 cells. In addition, Yes‑associated protein 1 (YAP1), a well‑known oncogene, was identified as a direct target of miR‑199a‑3p in OC cells. Additionally, it was observed that YAP1 was significantly increased and inversely correlated with miR‑199a‑3p expression in OC tissues. Notably, YAP1 overexpression abrogated the tumor suppressive effects of miR‑199a‑3p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.